Merck KGaA has teamed up with Selvita to discover small molecule drugs against multiple oncology indications. The alliance builds on an earlier two-year research collaboration into the discovery of enzyme inhibitors to regulate metabolic processes in cancer cells.
A group of marquee venture investors has joined forces to back a $40 million Series A for Crinetics Pharmaceuticals, an early-stage biotech in San Diego that has been working on a next-gen oral treatment for acromegaly.
Daiichi Sankyo picked up the FDA's breakthrough therapy designation for a Phase III cancer drug, putting it in line for preferential access to agency experts as it moves toward approval.
Gene therapy developer Voyager Therapeutics is angling for as much as $92 million in a planned IPO, braving choppy waters for biotech after a string of disappointing debuts for life sciences companies.
Novartis, Juno Therapeutics and Kite Pharma have made headlines around the world with a new technology for modifying T cells to better attack cancer. But translating clinical promise into a marketable product will likely prove difficult if and when so-called CAR-T therapies win approval.
Sanofi has backed away from a multiple sclerosis treatment developed alongside Indian drugmaker Glenmark Pharmaceuticals after the antibody came up short in a midstage trial.
Novartis won FDA approval for a combination COPD treatment it hopes can steal market share from entrenched rivals GlaxoSmithKline and Boehringer Ingelheim, planning to launch the inhaler next year.
Scientists in the U.K. say that AstraZeneca's drug olaparib, approved by the FDA late last year to treat ovarian cancer and sold as Lynparza, has demonstrated distinct signs of efficacy in a small and very targeted group of prostate cancer patients who share a distinct type of genetic mutation.
Repros Therapeutics is facing yet another setback for its long-delayed testosterone treatment as the FDA has backed out of a preapproval meeting and raised serious questions about the company's pivotal data.
In this week's EuroBiotech Report, Catalan biotech Grifols secured a €100 million ($110 million) loan from the European Investment Bank's €315 billion fund. The money will support a ratcheting up of R&D into Alzheimer's disease and other indications. And more.
Gilead Sciences, reaping billions from its duo of approved hepatitis C therapies, is moving toward the market with a third pill that promises to cure a wider range of patients with the virus.
Cellectis has completed three production runs of its off-the-shelf CAR-T therapy under GMP conditions. The news sent shares in Cellectis up by 20% in early trading in Paris, emphasizing the key role manufacturing know-how is seen as playing in the upcoming immuno-oncology scrap.
MD Anderson, which has attracted a who's who in immuno-oncology as partners for its Moon Shots R&D program, is adding 6 new cancers to its list of targets.
The rare disease specialists at Ultragenyx are turning to an upstart biotech for new platform technology.
BioBlast Pharma has posted a glimpse at the data that prompted it to wrap up a Phase II trial after enrolling just one-third of the targeted number of patients. And while there is very little data available publicly to support BioBlast's optimism, the company thinks it has a strong enough hand to start discussing a Phase III trial with FDA.
Oryzon Genomics has topped up its bank balance through a private placement months ahead of its anticipated listing on the Madrid Stock Exchange. The €16.6 million ($18.4 million) investment gives Oryzon the cash to keep pushing ahead with its pipeline plans in the months until it goes public.
Third Rock startup MyoKardia staggered onto Nasdaq on Wednesday, pricing its IPO at $10 a share--a deep, bargain basement discount from the hefty range it set for itself.
Grifols has become one of the first companies to receive cash under the €315 billion (€344 billion) Juncker Investment Offensive. The €100 million the European Investment Bank is funneling into Grifols will support a ratcheting up of R&D into the use of plasma proteins to treat Alzheimer's and other diseases.